STAAR SURGICAL (STAA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for STAA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| STAA | Member; Director; Special strategic advisor | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Experience with public company boards","Former Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC","Former Senior Vice President, China operations at AstraZeneca","Managing Director, China operations at Guidant Corporation","Various roles at Eli Lilly & Company including Marketing Director, China Operations"] | ["Science and Technology Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WAT | Independent Director | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Deep operational leadership experience in Asia-Pacific region's pharma and biopharma markets","Expertise in overseeing key business growth initiatives and partnerships","Knowledge on evolving complexities of Asia-Pacific region operations"] | ["Science and Technology"] | 2026 |
Biography sourced from the proxy statement filing.
Wei Jiang served as a member of the Board until April 2025 when he became a contracted advisor to STAAR. During his tenure on the Board, Mr. Jiang served on the Audit Committee and as Chair of the Nominating and Governance Committee until April 2025. Mr. Jiang has decades of significant and substantive China business and operational experience, and most recently served as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China Region, until his retirement in 2021. During his tenure on the Board, Mr. Jiang worked closely with STAAR's Asia Pacific team to understand the challenges and opportunities in this key region for STAAR. In 2025, Mr. Jiang was engaged as a special strategic advisor to the Company's Asia Pacific business through the end of fiscal 2025 in the temporary role of Chief of APAC Strategy, with the Board believing that Mr. Jiang's knowledge of the Company, business, strategy, and people, combined with his history of success in leadership roles at large multinational pharmaceutical companies in China, made him well suited for this role.